Novel cancer drug stymied by rigid billing system
The problem is that there is no billing code for the US$373,000 Yescarta therapy in Medicare
Minneapolis
A US government reimbursement system that does not fully cover the costs for Gilead Sciences Inc's complex blood cancer therapy is partly to blame for the slow uptake of the novel life-saving treatment, according to doctors who are trying to treat patients.
Only a handful of patients have received the therapy, Yescarta, two months after its approval, while waiting lists have risen to the hundreds at the 15 cancer centres authorised to administer the treatment in the US, Bloomberg News reported last Thursday.
The problem, said doctors at those centres, is that there is no billing code for the US$373,000 therapy in Medicare, the government plan that covers millions of elderly and disabled Americans. Gilead estimate…
BT is now on Telegram!
For daily updates on weekdays and specially selected content for the weekend. Subscribe to t.me/BizTimes
Consumer & Healthcare
Cutting the cord?: Events leading up to Cordlife’s MOH suspension and arrests of its directors, ex-group CEO
Billionaires selling cheap stuff get richer from inflation pain
Amazon to push cashierless shopping tech into more third-party stores, while backing off itself
Japan’s Uniqlo opens Rome store as part of European expansion
Abbott beats quarterly profit estimates on strong medical device sales
Adidas shares surpass two-year high as 'terrace' sneaker trend boosts brand heat